ClinicalTrials.gg
CompletedNCT05286346Updated May 16, 2025

Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B

A Phase 4 interventional study of Tenofovir disoproxil 245mg and Tenofovir disoproxil fumarate 300mg in Chronic Hepatitis b, sponsored by Samjin Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Samjin Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Oct 2018, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
27th of 50
113 · median 117
Started
2018
with 1 other
Phase 4
22 of 50
none open now
Registered
48th of 50
by date
Lead sponsor
2 of 50
Samjin Pharmaceutical Co., Ltd.

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 27th largest by enrollment, is one of 2 that started in 2018, is one of 22 in phase 4, and was the 48th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

This is a Phase4, multicenter, open-label, randomized study to demonstrate that the Tenolid Tab switching group is non-inferior to the virologic suppression effect compared to the Viread Tab continuous administration group and evaluate the safety of Tenolid Tab. This clinical trial was conducted on patients who were taking Viread Tab as monotherapy for more than 48 weeks for chronic hepatitis B.

At the time of screening(Visit 1), information on factors related to medical history and prognosis including Viread Tab administration were collected retrospectively from the subjects who voluntarily signed the informed consent form (ICF). Only subjects who are determined to be suitable for the study eligibility(inclusion/exclusion) criteria as a result of the screening evaluations are randomized in a 1:1 ratio to one of the two groups at the baseline.

Subjects will receive investigational product start on the next day of randomization for 48 weeks. Subjects will visit to the study site on 12, 24, 36, 24 weeks after starting dosing investigational product and evaluated for effectiveness of virologic suppression and safety.

03

Conditions studied

  • Chronic Hepatitis b

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. As of the date of written consent, adults aged 19 or above
  2. Patients with chronic
  3. For chronic hepatitis B, Viread Tab. monotherapy† for more than 48 weeks, HBV suppression‡(virologic suppression) was confirmed, and it was determined that Tenofovir monotherapy for more than 48 weeks would be required.

    † However, patients who take Viread Tab for more than 48 weeks before screening but do not take Viread Tab at the time of screening and discontinue the administration within 4 weeks until the time of randomization can be registered. (treatment gap ≤ 28 days)

    • HBV DNA \< 400 copies/mL (=69 IU/mL*) * IU/mL is converting to copies/mL by unit for each institution. (Ex: 5.8 copies/mL = 1 IU/mL)
  4. Subject who voluntarily consents to participate in the clinical trial and signs an

Exclusion criteria

Exclusion Criteria:

  1. Patients with liver cancer or decompensated liver cirrhosis* *Cirrhosis with clinical signs/symptoms of decompensation (jaundice, ascites, variceal bleeding, hepatic coma)
  2. Patients with virus (HCV), (HIV) with overlapping infections (HCV Ab positive, HIV Ab positive) However, if the HCV Ab or HIV Ab test result is judged to be 'false positive' by the investigator, HCV or HIV infection can be confirmed through additional confirmatory tests (HCV, HIV RNA test), etc.
  3. Patients with other liver disease (Hemochromatosis, Wilson's disease, Alcoholic liver disease, hepatitis, α-1 antitrypsin deficiency)
  4. Patients confirmed by laboratory test results as followings

    • Severe anemia: \< 8g/dL ② Inadequate renal function: (Ccr, formula) \< 50 mL/min ③ Inadequate hepatic function:

      • Total > 3.0 mg/dL
      • Albumin \< 2.8 mg/dL
      • (PT) > INR 2.2
  5. Patients with malignant tumors diagnosed within 5 years prior to screening However, in the case of basal cell carcinoma or squamouscell carcinoma of the skin, it is possible to participate in the clinical trial if it is judged to be 'cured' at the discretion of the investigator after surgery (treatment),.
  6. Patients who are scheduled for an organ transplantation or who have undergone organ transplantation surgery
  7. Patients with a history of clinically significant neuropsychiatric disorders, alcoholism, or drug dependence
  8. Patients known to have or allergy to components of products or similar drugs
  9. Patients who administered drugs within 24 weeks prior to screening or who administered systemic over a limited dose (equivalent to prednisolone 10 mg/day) for 4 consecutive weeks or more.
  10. Patients who are expected to require administration of the following drugs during the clinical trial period

    ① Immunosuppressive drug

    ② Systemic corticosteroids above a limited dose (equivalent to prednisolone 10 mg/day) for 2 consecutive weeks or more

    ③ Drugs affecting renal excretion, drugs inducing nephrotoxicity or hepatotoxicity

    ④ Anti- drugs other than Tenofovir (ex. emtricitabine, lamivudine, telbivudine, clevudine, entecavir, interferone)

    ⑤ Patients who administered hepatotonics at a stable dose for more than 3 months before screening can be registered.

  11. Those who have a history of fractures requiring bone mineral density (BMD) monitoring or are at risk of osteopenia, who are judged unable to participate in clinical trials according to the investigator's judgment
  12. For pregnant, lactating and reproductive women, patients who do not consent to by a medically accepted method (surgical sterilization, intrauterine device, condom or diaphragm) during the clinical trial period
  13. Patients who participated in another clinical trial within 12 weeks prior to screening and received investigational drugs or investigational devices.
  14. In addition to the above, subject considered ineligible to participate in this study by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Experimental group

    Tenolid Tab

    Drug: Tenofovir disoproxil 245mg

  • Active comparator
    Control group

    Viread Tab

    Drug: Tenofovir disoproxil fumarate 300mg

Interventions

06

What researchers measure

Primary outcomes

  1. Inhibiting† rate of HBV virus at 48 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) *IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)

    Time frame: 48 weeks

Secondary outcomes

  1. Inhibiting† rate of HBV virus at 12, 24 and 36 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) * IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)

    Time frame: 12, 24, 36 and 48 weeks

  2. Undetected‡ rate of HBV virus at 12, 24, 36 and 48 weeks after baseline ‡ The lower limit of quantification (LLOQ) for each institution is used, and if it is less than the LLOQ, the HBV DNA level is set to '0'.

    Time frame: 12, 24, 36 and 48 weeks

  3. Change of HBV DNA(log10 copies/mL) at 12, 24, 36 and 48 weeks from baseline

    Time frame: 12, 24, 36 and 48 weeks

  4. Loss rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline

    Time frame: 12, 24, 36 and 48 weeks

  5. Seroconversion† rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBe

    Time frame: 12, 24, 36 and 48 weeks

  6. Loss rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline ④ Seroconversion† rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBs

    Time frame: 12, 24, 36 and 48 weeks

  7. Seroconversion† rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBs

    Time frame: 12, 24, 36 and 48 weeks

  8. Normal rate of ALT at 12, 24, 36 and 48 weeks after baseline

    Time frame: 12, 24, 36 and 48 weeks

  9. Change of ALT at 12, 24, 36 and 48 weeks from baseline

    Time frame: 12, 24, 36 and 48 weeks

  10. Virologic breakthrough* rate within 48 weeks after baseline *HBV DNA ≥ 400 copies/mL: twice in a row at intervals of 2 weeks or more or HBV DNA levels: increasing by 1log10 from Nadir levels of each subject twice in a row (HBV DNA <400 copies/mL)

    Time frame: 12, 24, 36 and 48 weeks

07

Study locations

1 site
  • Dong-A University Hospital
    Busan, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2020, 21 months.

Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2022
First posted
Mar 18, 2022
StartActual
Oct 12, 2018
Primary completionActual
Aug 10, 2020
CompletionActual
Aug 10, 2020
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05286346
Lead sponsor
Samjin Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Oct 12, 2018
Primary completion
Aug 10, 2020
Completion
Aug 10, 2020
Last update
May 16, 2025

Study contacts

Seong Uk Lee
principal investigator · Dong-A University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion